SCIENTIFIC TALK AMD | 7 novembre 2022 | ore 17
Leggi
Efficacy and safety of dapagliflozin according to frailty in patients with heart failure: a prespecified analysis of the DELIVER Trial
Butt JH, Jhund PS, Belohlávek J, et al.
Circulation. 2022;146(16):1210-1224.
Leggi
Comparative effectiveness of empagliflozin vs liraglutide or sitagliptin in older adults with diverse patient characteristics
Htoo PT, Tesfaye H, Schneeweiss S, et al.
JAMA Netw Open. 2022;5(10):e2237606.
Leggi
Impact of inpatient initiation of sodium-glucose cotransporter-2 inhibitors on prescription rates in patients with heart failure with reduced ejection fraction
Okoroike H, Patel S, Simone P, et al.
The American Journal of Cardiology. Pub. online 22 Oct 2022.
Leggi
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
Biegus J, Voors AA, Collins SP, et al.
Eur Heart J. 2022;ehac530.
Leggi
Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs
Volke V, Katus U, Johannson A, et al.
BMC Endocr Disord. 2022;22(1):251.
Leggi
Trends in the association between diabetes and cardiovascular events, 1994-2019
Ke C, Lipscombe LL, Weisman A, et al.
JAMA. Pub. online 14 Oct 2022.
Leggi
Myocardial extracellular volume expansion in type 2 diabetes is associated with ischemic heart disease, autonomic neuropathy, and active smoking
Boje AS, Sørensen MH, Gæde P, Madsen PL
Diabetes Care. 2022;dc220942.
Leggi
Improving CGM uptake in underserved youth with type 1 diabetes: the IMPACT study
Lin T, Manfredo JA, Illesca N, et al.
Diabetes Technol Ther. Pub. online 12 Oct 2022.
Leggi
Investigating the causal relationships between excess adiposity and cardiometabolic health in men and women
Mutie PM, Pomares-Milan H, Atabaki-Pasdar N, et al.
Diabetologia. Pub. online 12 Oct 2022.
Leggi